Adagene (ADAG) to Release Earnings on Wednesday

Adagene (NASDAQ:ADAG) is projected to announce its Q2 2026 resultson Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $17.50 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Adagene Stock Down 4.6%

NASDAQ ADAG opened at $3.51 on Tuesday. The business has a fifty day moving average price of $3.88 and a 200 day moving average price of $3.70. Adagene has a one year low of $1.30 and a one year high of $4.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.02 and a quick ratio of 3.07.

Insider Buying and Selling at Adagene

In related news, CEO Peter Luo bought 22,966 shares of the stock in a transaction dated Tuesday, August 4th. The shares were acquired at an average cost of $3.65 per share, for a total transaction of $83,825.90. Following the acquisition, the chief executive officer directly owned 67,966 shares in the company, valued at approximately $248,075.90. This trade represents a 51.04% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders purchased 25,245 shares of company stock worth $92,344. Insiders own 21.20% of the company’s stock.

Institutional Investors Weigh In On Adagene

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Exome Asset Management LLC purchased a new position in Adagene during the fourth quarter worth approximately $2,004,000. Citadel Advisors LLC purchased a new stake in Adagene in the 3rd quarter valued at $80,000. SmartHarvest Portfolios LLC purchased a new stake in Adagene in the 4th quarter valued at $73,000. Finally, Marex Group plc acquired a new stake in shares of Adagene in the 2nd quarter worth $47,000. Institutional investors and hedge funds own 9.51% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ADAG. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adagene in a research note on Friday, July 17th. Guggenheim reiterated a “buy” rating and issued a $10.00 target price on shares of Adagene in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.